Overview

Repeated Neurocognitive Measurements in Depressed Patients

Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
In this project, we will A) track the functioning of a collection of potential neurobiological targets for depression over time, B) examine how fluctuations in the functioning of those targets relates to real-world functioning, and C) in a subset of the sample, determine how the functioning in those targets is altered by a single dose of ketamine.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Rebecca Price
Treatments:
Ketamine